A Phase II Evaluation of PS-341 (NSC# 681239) in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2010 Actual end date (1 Jan 2010) added as reported by ClinicalTrials.gov record.
- 09 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2009 Primary endpoints added as reported by ClinicalTrials.gov.